News
Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified interim analysis, where Pluvicto (lutetium (177 Lu) vipivotide tetraxetan), plus standard of care (SoC ...
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus ...
Dr Petros Grivas reflects on ASCO 2025 highlights, including new data on PARP inhibitors and the growing importance of biomarker-driven treatment.
Dr Petros Grivas discusses updates in biomarker-driven therapies and emerging treatment strategies from the STAMPEDE, AMPLITUDE, and PSMAddition trials.
The company noted that the Phase III PSMAddition trial met its primary endpoint for Pluvicto plus hormone therapy versus hormone therapy alone, with positive trend in overall survival.
Novartis Says Phase III PSMAddition Trial Met Its Primary Endpoint Published: June 2, 2025, 1:39 a.m. ET Share Resize ...
Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified interim analysis, where Pluvicto (lutetium (177 Lu) vipivotide tetraxetan), plus standard of care (SoC ...
Novartis announced topline results from a pre-specified interim analysis of the phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically ...
At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for PluvictoTM plus hormone therapy versus hormone therapy alone ...
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results